Novel inhibitors of human IDO1 and TDO

被引：1
|
作者：
Banerjee, Monali
Middya, Sandip
Shrivastava, Ritesh
Raina, Sushil
Yadav, Dharmendra
Singh, Satveer
Manna, Anindita
Chakraborty, Debjani
Surya, Arjun
机构：
来源：
CANCER IMMUNOLOGY RESEARCH | 2015年 / 3卷 / 10期
关键词：
D O I：
10.1158/2326-6074.TUMIMM14-A59
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A59
引用
收藏
页数：1
相关论文
共 50 条
  • [41] IN VITRO KYNURENINE MODULATION BY NOVEL DUAL-ACTING AND SELECTIVE TDO AND IDO INHIBITORS
    Alan, Wise
    Barry, Mcguinness E.
    Phillip, Cowley M.
    Sarah, Trewick C.
    Nicola, Bevan
    Clare, Szybut
    Thomas, Brown J.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S5 - S5
  • [42] TARGETING IDO1 IN HUMAN PEDIATRIC BRAIN CANCER
    Lauing, Kristen
    Lulla, Rishi
    Lenzen, Alicia
    Zhai, Lijie
    Hashizume, Rintaro
    Fangusaro, Jason R.
    Wainwright, Derek
    NEURO-ONCOLOGY, 2017, 19 : 120 - 120
  • [43] Co Recombination in Human IDO and TDO - A Comparison
    Nienhaus, Karin
    Nienhaus, G. Ulrich
    BIOPHYSICAL JOURNAL, 2014, 106 (02) : 676A - 676A
  • [44] Investigation of the absolute bioavailability and human mass balance of navoximod, a novel IDO1 inhibitor
    Ma, Shuguang
    Suchomel, Julia
    Yanez, Evelyn
    Yost, Edward
    Liang, Xiaorong
    Zhu, Rui
    Le, Hoa
    Siebers, Nicholas
    Joas, Lori
    Morley, Roland
    Royer-Joo, Stephanie
    Pirzkall, Andrea
    Salphati, Laurent
    Ware, Joseph A.
    Morrissey, Kari M.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (08) : 1751 - 1760
  • [45] Amyloid β neurotoxicity is IDO1–Kyn–AhR dependent and blocked by IDO1 inhibitor
    Zhenzhen Duan
    Shengnan Zhang
    Heng Liang
    Zikang Xing
    Leilei Guo
    Lei Shi
    Lisha Du
    Chunxiang Kuang
    Osamu Takikawa
    Qing Yang
    Signal Transduction and Targeted Therapy, 5
  • [46] High TDO and IDO1 expression in ovarian cancer-associated cells isolated from malignant ascites
    van Riel, Wilhelmina
    van Doornmalen, Antoon
    Mulder, Winfried
    Vu, Diep
    Dylus, Jelle
    den Ouden, Judith
    van Altena, Anne
    Buijsman, Rogier
    Zaman, Guido
    CANCER RESEARCH, 2020, 80 (16)
  • [47] Is There a Clinical Future for IDO1 Inhibitors After the Failure of Epacadostat in Melanoma?
    Van den Eynde, Benoit J.
    van Baren, Nicolas
    Baurain, Jean-Francois
    ANNUAL REVIEW OF CANCER BIOLOGY, VOL 4, 2020, 4 : 241 - 256
  • [48] Synthesis and biological evaluation of biaryl alkyl ethers as inhibitors of IDO1
    Markwalder, Jay A.
    Balog, Aaron J.
    Williams, David K.
    Nara, Susheel J.
    Reddy, Ratnakar
    Roy, Saumya
    Kanyaboina, Yadagiri
    Li, Xin
    Johnston, Kathy
    Fan, Yi
    Lewis, Hal
    Marsilio, Frank
    Yan, Chunhong
    Critton, David
    Newitt, John A.
    Traeger, Sarah C.
    Wu, Dauh-Rurng
    Jure-Kunkel, Maria N.
    Jayaraman, Lata
    Lin, Tai-An
    Sinz, Michael W.
    Hunt, John T.
    Seitz, Steven P.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2023, 88
  • [49] Design, synthesis and biological evaluation of exiguamine A analogues as IDO1 inhibitors
    Dong, Junmin
    Pan, Xuan
    Yang, Ying
    Zhang, Guangyan
    Xiao, Zhiyan
    Liu, Zhanzhu
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 223
  • [50] Structure-activity Relationship of Indomethacin Derivatives as IDO1 Inhibitors
    Obata, Tohru
    Shiratani, Sara
    Nada, Tomomi
    Kasaya, Yayoi
    Arisawa, Mitsuhiro
    Shuto, Satoshi
    Tanaka, Motohiro
    ANTICANCER RESEARCH, 2021, 41 (05) : 2287 - 2296
12345